Vol 5, Supplement 2 (August 2016): Translational Cancer Research


Gut microbia dysbiosis in non-alcoholic fatty liver disease
Debra A. Guss, Smruti R. Mohanty
Metformin: a promising candidate for chemoprevention of colorectal tumor and its future
Tae Il Kim
Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components
Brandon J. Manley, James J. Hsieh
Adjuvant therapy in early-stage small-cell lung cancer: what’s new?
Antonio Rossi
Recent randomized trials on stage III lung cancer treatment
Chi-Fu Jeffrey Yang, Thomas A. D’Amico
“Switchable chimeric antigen receptor T cells: a novel universal chimeric antigen receptor platform for a safe control of T-cell activation”
Silvia Arcangeli, Chiara F. Magnani, Sarah Tettamanti, Ettore Biagi
Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives
Lena-Christin Conradi, Florian Lordick, Andreas Pircher
Towards prevention of metastatic prostate cancer: recent molecular insights from the direct analysis of metastatic precursor cells
Miodrag Gužvić, Christoph A. Klein
Genomic analysis of pancreatic cancer: a glimmer of hope for the therapy?
Simone Polvani, Andrea Galli
Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?
Chen-Hua Liu, Jia-Horng Kao
The role of circadian clock genes in leukemia
Ming-Yu Yang, Sheng-Fung Lin
PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
Yusuke Inoue, Murat Osman, Takafumi Suda, Haruhiko Sugimura
Positron emission tomography-CT surveillance versus neck dissection in advanced head and neck cancer: time for a paradigm shift in management
Jason I. Kass, Vikas Mehta
Exosomes as “translational” cancer promoter organelles
Isabella Panfoli
Trans-arterial embolization for hepatocellular carcinoma: with or without epidoxorubicin?
Alessandro Cucchetti, Alberta Cappelli, Rita Golfieri
Calculation of recurrence risk of ductal carcinoma in situ: open questions, controversies and future perspectives
Menelaos Zafrakas
Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Fabiana Perna, Michel Sadelain
Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells
Alex J. Gooding, William P. Schiemann
Tumor recurrence in patients treated with direct-acting antivirals for hepatitis C following curative therapy: a cause for concern?
Sevan Evren, David K. H. Wong
Promise of vandetanib, a FDA-approved RET kinase inhibitor, for the treatment of RET fusion-positive lung adenocarcinoma
Takashi Kohno
Pazopanib: a new therapeutic option for advanced gastrointestinal stromal tumors
George Z. Li, Chandrajit P. Raut
Actionable intelligence provided by pancreatic cancer genomic landscape: are targets for curative therapy on the map?
Nathan A. Berger
GD3 mediated immune response via vascular endothelial growth factor in ovarian cancer
Aristotle Bamias, Nikos G. Gavalas
HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?
Andrew J. Scott, John C. Wilkinson
Functional and clinical impact of MYC mutations in diffuse large B cell lymphomas
Nathalie A. Johnson
Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability
Constance Michel, Constance Thibault, Stephane Oudard
TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?
Derek B. Oien, Jeremy Chien
Crucial role of vascular endothelial growth factor in the immune system of patients with ovarian cancer
Yasuto Kinose, Kenjiro Sawada, Tadashi Kimura


Tumor-associated neutrophils: an emerging player in the immune microenvironment of hepatocellular carcinoma
Li-Chun Lu, Chih-Hung Hsu
The expanding role of exosomes in cancer biology and therapy
Edward Sauter
Tumor-infiltrating T cells are invigorated by modulating cholesterol metabolism
Erica L. Stone, Louise M. D’Cruz
Epidermal growth factor receptor-tyrosine kinase inhibitors, which is the best choice?
Tetsuya Oguri
CCR5 antagonist, an ally to fight against metastatic colorectal cancer
Naofumi Mukaida
Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition
Claus Garbe
Chimeric antigen receptor T cells get passed by leukemia
Frederick L. Locke, Marco L. Davila
Pancreatic ductal adenocarcinoma—a new hope?
Glen R. B. Irving, Dileep N. Lobo
Urinary exosome and beyond
Yu-Ru Liu, Yi-Fen Lee
Immunoscore vs. Microsatellite instability as prognostic biomarkers in colorectal cancer: who wins?
Constantin N. Baxevanis
Divergent roles of miR-126 in normal and malignant stem cells
Harold K. Elias, Mona Khalaj, Christopher Y. Park
Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer
Aziz Zaanan, Simon Pernot, Julien Taieb
p-21 activated kinase 4 (PAK4) role in pancreatic cancer stem cells
Marta Herreros-Villanueva, Luis Bujanda
Helios—controller of Treg stability and function
Claire Chougnet, David Hildeman
Dabrafenib in patients with BRAF-mutated non-small cell lung cancer
Takahisa Kawamura, Haruyasu Murakami
Deep sequencing reveals that low level TP53 mutations are ubiquitous in ovarian cancer patients and controls: successes and challenges for early detection
Hugues Sicotte
Sweetening of glutamine metabolism in cancer cells by Rho GTPases through convergence of multiple oncogenic signaling pathways
Thambi Dorai, John T. Pinto, Arthur J. L. Cooper
CRISPR/Cas9 engineering offers new opportunities to model pancreatic ductal adenocarcinoma development
Claus Jørgensen, Elizabeth K. J. Hogg
An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer
Kristopher A. Lofgren, Paraic A. Kenny


This supplement was published without any sponsorship or funding.